Loading...
PRTA logo

Prothena Corporation plcNasdaqGS:PRTA Stock Report

Market Cap US$441.4m
Share Price
US$8.20
My Fair Value
US$15
45.3% undervalued intrinsic discount
1Y-63.2%
7D-6.5%
Portfolio Value
View

Prothena Corporation plc

NasdaqGS:PRTA Stock Report

Market Cap: US$441.4m

Prothena (PRTA) Stock Overview

A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. More details

PRTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PRTA Community Fair Values

Create Narrative

See what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.

Prothena Corporation plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Prothena
Historical stock prices
Current Share PriceUS$8.20
52 Week HighUS$22.83
52 Week LowUS$4.32
Beta-0.033
1 Month Change20.41%
3 Month Change75.97%
1 Year Change-63.18%
3 Year Change-69.53%
5 Year Change-38.30%
Change since IPO13.89%

Recent News & Updates

The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts

May 29
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts

Recent updates

The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts

May 29
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts

Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place

May 27

Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge

May 22
Why Investors Shouldn't Be Surprised By Prothena Corporation plc's (NASDAQ:PRTA) 27% Share Price Plunge

Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet

Apr 02
Benign Growth For Prothena Corporation plc (NASDAQ:PRTA) Underpins Stock's 26% Plummet
User avatar

AFFIRM-AL And Alzheimer's Trials Will Unlock New Opportunities

Successful clinical trials for Birtamimab and Alzheimer's treatments could significantly boost Prothena's revenue through large market opportunities.

Prothena Corporation: Multiple Failures Make It Risky

Mar 03

Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think

Feb 22
Prothena Corporation plc (NASDAQ:PRTA) Just Released Its Yearly Earnings: Here's What Analysts Think

Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price

Jan 24
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price

Prothena Surges After Parkinson's Drug Misses Primary Endpoint

Dec 22

Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans

Nov 06
Prothena (NASDAQ:PRTA) Is In A Good Position To Deliver On Growth Plans

Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)

Oct 18

Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Oct 02
Prothena Corporation plc (NASDAQ:PRTA) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Jul 26
Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Jun 19
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials

Jun 07

New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

May 14
New Forecasts: Here's What Analysts Think The Future Holds For Prothena Corporation plc (NASDAQ:PRTA)

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Feb 08
Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Dec 20
Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Nov 24
Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Oct 27
Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Aug 25
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

May 10
What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Apr 23
We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Mar 01
Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Shareholder Returns

PRTAUS BiotechsUS Market
7D-6.5%-1.8%0.01%
1Y-63.2%-9.9%15.7%

Return vs Industry: PRTA underperformed the US Biotechs industry which returned -10% over the past year.

Return vs Market: PRTA underperformed the US Market which returned 15.8% over the past year.

Price Volatility

Is PRTA's price volatile compared to industry and market?
PRTA volatility
PRTA Average Weekly Movement7.0%
Biotechs Industry Average Movement10.5%
Market Average Movement6.4%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: PRTA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: PRTA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012163Gene Kinneywww.prothena.com

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.

Prothena Corporation plc Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
PRTA fundamental statistics
Market capUS$441.41m
Earnings (TTM)-US$302.92m
Revenue (TTM)US$10.34m
42.7x
P/S Ratio
-1.5x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRTA income statement (TTM)
RevenueUS$10.34m
Cost of RevenueUS$192.22m
Gross Profit-US$181.88m
Other ExpensesUS$121.04m
Earnings-US$302.92m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.63
Gross Margin-1,758.84%
Net Profit Margin-2,929.30%
Debt/Equity Ratio0%

How did PRTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/31 15:58
End of Day Share Price 2025/08/29 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prothena Corporation plc is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Tazeen AhmadBofA Global Research
null nullBTIG